➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKinsey
Express Scripts
Merck
Dow

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for KAF156

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for KAF156?

KAF156 is an investigational drug.

There have been 4 clinical trials for KAF156. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP), and [disabled in preview].

There are three US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for KAF156
TitleSponsorPhase
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum MalariaEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Phase 2
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum MalariaNovartis PharmaceuticalsPhase 2
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum MalariaNovartis PharmaceuticalsPhase 2

See all KAF156 clinical trials

Clinical Trial Summary for KAF156

Top disease conditions for KAF156
Top clinical trial sponsors for KAF156

See all KAF156 clinical trials

US Patents for KAF156

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
KAF156   Start Trial Compounds and compositions useful for the treatment of parasitic diseases IRM LLC (Hamilton, BM)   Start Trial
KAF156   Start Trial Compounds and compositions for the treatment of parasitic diseases Novartis AG (Basel, CH)   Start Trial
KAF156   Start Trial Compounds and compositions for the treatment of parasitic disease Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for KAF156

Drugname Country Document Number Estimated Expiration Related US Patent
KAF156 Argentina AR077463 2029-07-09   Start Trial
KAF156 Australia AU2010271247 2029-07-09   Start Trial
KAF156 Brazil BR112012000413 2029-07-09   Start Trial
KAF156 Canada CA2767664 2029-07-09   Start Trial
KAF156 Chile CL2012000042 2029-07-09   Start Trial
KAF156 China CN102471341 2029-07-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKinsey
Express Scripts
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.